AnaptysBio Inc. Stock Nearly Doubles on Positive Clinical Trial Results

On October 10, AnaptysBio Inc. (ANAB) reported positive results from its Phase 2a clinical trial of a drug to treat atopic dermatitis. Based on the current clinical trial results, the efficacy of this drug is much higher than other similar drugs on the market for the treatment of moderate-to-severe atopic dermatitis. Multiple studies also indicate the drug could be helpful to patients with asthma and food allergies.

 

Sonal caught the news and issued an alert at 6:30 am. The next trade occurred at 7:02 am during pre-market trading for $36.

After the initial price surge, the stock price experienced a fade during the pre-market trading hours. The price rose again to $53.21 at the opening of regular market trading. The price continued to rise throughout the day to a closing price of $70.41. That marks a gain of 95.5% from the Sonal alert to the close of trading later that same day.

 

If you want to learn more about trading on clinical trial results, visit the Knowledge Center.

To see the latest weekly webinar, you can visit our Live Webinar page.

Subscribe here if you would like to start receiving these signals in real-time and start trading!